We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

218 hedge funds and large institutions have $1.1B invested in Iovance Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 71 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more call options, than puts

Call options by funds: $9.1M | Put options by funds: $3.82M

18% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 71

11.9% more ownership

Funds ownership: 97.76% → 109.66% (+12%)

10% less funds holding

Funds holding: 242 → 218 (-24)

25% less capital invested

Capital invested by funds: $1.45B → $1.1B (-$356M)

45% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 47

Holders
218
Holders Change
-24
Holders Change %
-9.92%
% of All Funds
3.5%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
84
Reduced
71
Closed
47
Calls
$9.1M
Puts
$3.82M
Net Calls
+$5.28M
Net Calls Change
-$11.1M

Top Buyers

1
MFM
MHR Fund Management
New York
+$93.7M
2
State Street
State Street
Massachusetts
+$37.3M
3
Morgan Stanley
Morgan Stanley
New York
+$30.6M
4
Renaissance Technologies
Renaissance Technologies
New York
+$18.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$14.5M

Top Sellers

1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$27.7M
2
ACA
Avoro Capital Advisors
New York
-$15.6M
3
Franklin Resources
Franklin Resources
California
-$14.7M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$13.6M
5
APM
Avidity Partners Management
Texas
-$13.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
51
Vivo Capital
California
$4.19M – – –
Barclays
52
Barclays
United Kingdom
$4.03M +$1.88M +240,344 +62%
CSS
53
Cubist Systematic Strategies
Connecticut
$3.95M +$1.25M +160,674 +35%
Bank of New York Mellon
54
Bank of New York Mellon
New York
$3.83M -$870K -111,457 -16%
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$3.78M +$211K +27,028 +5%
BPC
56
Banque Pictet & Cie
Switzerland
$3.62M -$227K -29,040 -5%
KCM
57
Kennedy Capital Management
Missouri
$3.6M -$863K -110,491 -16%
Capital Fund Management (CFM)
58
Capital Fund Management (CFM)
France
$3.44M +$3.42M +437,434 +436%
Citigroup
59
Citigroup
New York
$3.32M -$397K -50,824 -9%
Jacobs Levy Equity Management
60
Jacobs Levy Equity Management
New Jersey
$2.95M +$2.16M +276,063 +149%
PAMS
61
Pictet Asset Management (Switzerland)
Switzerland
$2.81M -$27.7M -3,542,635 -89%
Wellington Management Group
62
Wellington Management Group
Massachusetts
$2.69M -$9.51M -1,217,925 -74%
RCAMU
63
Rothschild & Co Asset Management US
Connecticut
$2.68M -$249K -31,948 -7%
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$2.62M +$1.92K +246 +0.1%
AG
65
Algert Global
California
$2.5M +$373K +47,720 +14%
AAA
66
Affinity Asset Advisors
New York
$2.4M +$2.93M +375,000 New
Marshall Wace
67
Marshall Wace
United Kingdom
$2.36M +$2.88M +369,463 New
AllianceBernstein
68
AllianceBernstein
Tennessee
$2.13M +$1.27M +162,401 +95%
LOAMS
69
Lombard Odier Asset Management (Switzerland)
Switzerland
$2.1M – – –
American Century Companies
70
American Century Companies
Missouri
$2.03M -$1.19M -152,927 -32%
Hudson Bay Capital Management
71
Hudson Bay Capital Management
Connecticut
$1.97M +$1.62M +208,000 +208%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
72
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.92M +$2.34M +300,000 New
SEI Investments
73
SEI Investments
Pennsylvania
$1.89M +$70.6K +9,041 +3%
PCM
74
Peregrine Capital Management
Minnesota
$1.87M +$396K +50,671 +21%
Swiss National Bank
75
Swiss National Bank
Switzerland
$1.83M +$48.4K +6,200 +2%
1 2
3
4 5

IOVA Hedge Fund Activity: Q4 2022 in Review

218 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2022, worth a combined $1.1B — down 25% from $1.45B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of IOVA and 26 opened new positions — a net loss of 21 holders — while 71 trimmed existing stakes and 84 added.

The largest buyer was MHR Fund Management, opening a new position worth an estimated $93.7M. The largest seller was Pictet Asset Management (Switzerland), cutting an estimated $27.7M.

  • 218 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2022, down from 242 in Q3 2022.
  • Funds reported $1.1B of Iovance Biotherapeutics stock for Q4 2022, down 25% quarter-over-quarter.
  • 26 funds opened new Iovance Biotherapeutics positions in Q4 2022 and 47 closed out, a net change of -21 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2022 was MHR Fund Management, an estimated $93.7M added.
  • The largest Iovance Biotherapeutics seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $27.7M sold.

Based on aggregated 13F filings for Q4 2022.